Garsorasib (D-1553) is a potent and selective oral KRASG12C inhibitor with antitumor activity. It has the potential to treat non-small cell lung cancer (NSCLC) with KRAS G12C mutation.

 

Brand: BCM

 

Target: Ras

 

Signaling Pathways: GPCR/G Protein; MAPK

 

Boiling Point: 768.9±70.0 °C(Predicted)

 

pKa: 3.36±0.28(Predicted)

 

Solubility: Soluble in DMSO; soluble in Ethanol. Insoluble in Water.

 

Isomeric SMILES: C[C@@H]1CN([C@H](CN1C(=O)C=C)C)C2=NC(=O)N(C3=NC(=C(C=C32)F)C4=C(C=CC=C4F)N)C5=C(N=CN=C5C6CC6)C7CC7  

 

InChIKey: DKFRWZJCNPETGI-SJORKVTESA-N  

 

InChI: InChI=1S/C32H32F2N8O2/c1-4-24(43)40-13-17(3)41(14-16(40)2)30-20-12-22(34)28(25-21(33)6-5-7-23(25)35)38-31(20)42(32(44)39-30)29-26(18-8-9-18)36-15-37-27(29)19-10-11-19/h4-7,12,15-19H,1,8-11,13-14,35H2,2-3H3/t16-,17+/m1/s1

 

Attribute
[Chem Name]	7-(2-amino-6-fluorophenyl)-1-(4,6-dicyclopropylpyrimidin-5-yl)-4-[(2S,5R)-2,5-dimethyl-4-prop-2-enoylpiperazin-1-yl]-6-fluoropyrido[2,3-d]pyrimidin-2-one
[Synonym]	Garsorasib; D-1553
[CAS No.]	2559761-14-5
[Formula]	C32H32F2N8O2
[Molecular]	598.65
[Form]	Solid powder
[Storage]	Sealed in dry. Stored at -20°C

Goods Tag